Growth Hormone and Somatic Growth

Growth hormone (somatotropin) is a 191-amino-acid, single-chain peptide hormone synthesized and secreted by somatotrophs, which make up about half of the cells in the anterior pituitary (adenohypophysis). Its release is governed by two opposing hypothalamic peptides delivered through the hypophyseal portal blood: growth hormone-releasing hormone (GHRH), which stimulates GH synthesis and secretion, and somatostatin (growth hormone-inhibiting hormone, GHIH), which suppresses secretion without much affecting synthesis. A third input, the "hunger hormone" ghrelin from the stomach, also stimulates GH release and partly explains why GH pulses are entrained to fasting and sleep. The defining conceptual move in GH physiology is separating direct from indirect actions. GH itself binds a cell-surface GH receptor and directly antagonizes insulin's effects on glucose and fat metabolism — this is sometimes called the "diabetogenic" or anti-insulin arm. But GH's growth-promoting, anabolic effects on cartilage, bone, and muscle are mediated overwhelmingly by insulin-like growth factor 1 (IGF-1, also historically called somatomedin C), a peptide whose transcription GH induces in the liver and in target tissues themselves (autocrine/paracrine IGF-1). IGF-1 is structurally similar to proinsulin and signals through its own receptor tyrosine kinase (IGF-1R), distinct from the GH receptor. The system is closed by classic long-loop negative feedback: circulating IGF-1 acts on both the hypothalamus (suppressing GHRH, stimulating somatostatin) and the pituitary (suppressing somatotroph responsiveness to GHRH), and GH itself feeds back to stimulate hypothalamic somatostatin release — a short-loop feedback. This dual-hormone, dual-target feedback architecture recurs throughout the Hypothalamus-Pituitary Axis and is a template for the thyroid and adrenal axes as well.

Step 1 — Pulsatile secretion. GH is released in discrete bursts, mainly during slow-wave sleep (the largest pulse typically occurs about an hour after sleep onset) and after exercise or fasting, with plasma concentrations that spike from a baseline near 1–5 ng/mL to peaks of 10–40 ng/mL and then fall over 1–2 hours. GHRH neurons in the arcuate nucleus fire episodically, driving each pulse, while somatostatin neurons in the periventricular nucleus set the troughs. This pulsatility itself matters physiologically: continuous, non-pulsatile GH exposure is far less effective at stimulating growth than the same total dose delivered in pulses, because sustained receptor occupancy down-regulates the GH receptor–JAK2–STAT5 signaling cascade.

Step 2 — Receptor binding and JAK2-STAT5 signaling. GH binds a preformed dimer of GH receptors (a type I cytokine receptor family member) on target-cell membranes. Binding activates the receptor-associated cytoplasmic tyrosine kinase JAK2, which phosphorylates itself and the receptor's cytoplasmic tail. This recruits and phosphorylates STAT5 transcription factors, which dimerize, translocate to the nucleus, and induce transcription of target genes — most importantly the IGF-1 gene in hepatocytes and in chondrocytes, osteoblasts, and myocytes. The same JAK2-STAT5 pathway also up-regulates lipases in adipocytes (direct metabolic effect) and induces suppressor of cytokine signaling (SOCS) proteins that self-limit the signal.

Step 3 — Two parallel outputs from one receptor. Direct (anti-insulin) actions of GH, occurring within minutes to hours, mediated by GH acting on its receptor in muscle, liver, and fat without requiring IGF-1:

• Decreased glucose uptake into muscle and fat (GH antagonizes insulin-stimulated GLUT4 translocation).
• Increased hepatic glucose output (gluconeogenesis).
• Increased lipolysis in adipose tissue, releasing free fatty acids that are then oxidized preferentially as fuel, sparing glucose and amino acids — the "protein-sparing, glucose-sparing, fat-mobilizing" triad.

These direct actions explain why excess GH is diabetogenic and why fasting (which raises GH) shifts fuel use toward fat. Indirect (growth-promoting) actions, occurring over days, mediated by IGF-1:

• Hepatic IGF-1 enters the circulation bound to IGF-binding proteins (mainly IGFBP-3, in a ternary complex with an acid-labile subunit), which prolongs its half-life to hours (versus minutes for free IGF-1) and buffers its delivery to tissues.
• Local (paracrine/autocrine) IGF-1 is produced directly in the epiphyseal growth plate's chondrocytes, in bone-forming osteoblasts, and in skeletal muscle, and acts locally without needing to enter the systemic circulation — this local production is now understood to matter at least as much as liver-derived IGF-1 for skeletal growth.
• IGF-1 binds IGF-1R, a receptor tyrosine kinase structurally related to the insulin receptor, activating the PI3K–Akt and Ras–MAPK pathways to drive cell proliferation, protein synthesis, and suppression of apoptosis.

Step 4 — Growth plate mechanics. In the epiphyseal (growth) plate, GH acts on prechondrocyte stem cells to commit them to the chondrocyte lineage and to stimulate local IGF-1 production; IGF-1 then drives clonal expansion of chondrocytes in the proliferative zone. These chondrocytes enlarge (hypertrophic zone), mineralize their matrix, and are replaced by bone as osteoblasts invade — the process of endochondral ossification that lengthens long bones. This continues until rising sex-steroid levels at puberty (estrogen in both sexes) trigger terminal chondrocyte differentiation and epiphyseal plate closure, permanently ending longitudinal bone growth — which is why GH excess in adulthood cannot make bones longer, only thicker.

Step 5 — Negative feedback closes the loop. Rising IGF-1 acts at the hypothalamus to inhibit GHRH neurons and stimulate somatostatin neurons, and at the pituitary to reduce somatotroph sensitivity to GHRH. GH itself also stimulates hypothalamic somatostatin release (short-loop feedback), and high glucose and free fatty acids acutely suppress GH secretion, linking the axis back to Glucose Homeostasis and the Endocrine Pancreas.

The somatomedin hypothesis and the Salmon-Daughaday experiment (1957). Before the 1950s, physiologists assumed GH acted directly on cartilage to stimulate growth, since hypophysectomized (pituitary-removed) animals stopped growing and GH injections restored growth. William Daughaday and William Salmon tested this assumption directly using an elegant in vitro bioassay: cartilage explants from hypophysectomized rats were incubated with radioactive sulfate (³⁵SO₄²⁻), and the incorporation of sulfate into cartilage proteoglycans (a proxy for cartilage growth) was measured. The critical result: adding purified GH directly to the cartilage culture medium in a test tube produced no increase in sulfate incorporation. But injecting GH into an intact (or hypophysectomized) animal and then taking that animal's serum and adding it to the cartilage culture did stimulate sulfate uptake dramatically. This proved that GH does not act directly on cartilage; instead, GH induces the liver (and other tissues) to produce a separate circulating factor — originally named "sulfation factor," later "somatomedin," and finally identified biochemically in the late 1970s as insulin-like growth factor 1 (IGF-1) by Judson Van Wyk, Rene Humbel, and colleagues who purified and sequenced the peptide and showed its structural homology to proinsulin. This single experiment reoriented the entire field: GH's growth-promoting effects are indirect, and any complete model of somatotropic control needs a second hormone. Later work (radioimmunoassays for IGF-1, IGF-1 receptor cloning, and IGF-1 knockout mice in the 1990s by Argiris Efstratiadis and colleagues, which showed severe intrauterine growth retardation and neonatal lethality) confirmed IGF-1's central causal role and refined the model to include local paracrine IGF-1 production alongside the liver-derived endocrine pool.

Hypophysectomy and replacement classics. Earlier still, experiments by Herbert Evans and colleagues in the 1920s–30s showed that hypophysectomized rats stopped growing and became dwarfed, while daily injection of crude anterior pituitary extract restored normal growth rates — establishing that a pituitary factor, later purified as GH, was necessary and sufficient (in the presence of a normal liver) for postnatal somatic growth. Evans's laboratory also produced experimental gigantism by chronic administration of pituitary extracts to young rats, directly linking GH excess to accelerated linear growth — a forerunner of the clinical syndrome of pituitary gigantism.

Laron dwarfism as a natural experiment. Zvi Laron described a cohort of patients in the 1960s with short stature, high circulating GH, but very low IGF-1 — the opposite pattern from GH deficiency. This was later shown to result from mutations in the GH receptor gene, so that GH is secreted normally (even in excess, due to loss of feedback) but cells cannot respond to it or generate IGF-1. Laron dwarfism is a human "knockout" of GH receptor function and is a powerful confirmatory case for the whole GH→IGF-1→growth causal chain: without a functional receptor, GH alone cannot promote growth no matter how high its concentration.

Example 1 — Interpreting a growth-hormone stimulation test. A 9-year-old boy is 15 cm below the 3rd percentile for height, with a growth velocity of 3 cm/year (normal prepubertal velocity is about 5–6 cm/year). His physician orders an insulin tolerance test (insulin-induced hypoglycemia is a potent physiological GH stimulus) with serial GH measurements.

Adequate hypoglycemic stress was achieved (glucose fell below 40 mg/dL, satisfying the criterion for a valid test), yet peak GH (1.5 ng/mL) remains far below the diagnostic threshold for a normal response (typically >7–10 ng/mL depending on assay). This is consistent with GH deficiency rather than a failed test. A follow-up IGF-1 level is measured and found to be low for age, corroborating the diagnosis (a low IGF-1 alone is not diagnostic, since it's also affected by malnutrition and liver disease, but combined with a flat GH stimulation test it strongly supports GH deficiency). The boy is a candidate for recombinant human GH therapy; the earlier treatment starts relative to epiphyseal fusion, the more total height can be recovered, because the therapeutic window closes once growth plates ossify.

Example 2 — Acromegaly: reasoning through metabolic and skeletal changes. A 45-year-old woman presents with enlarged hands and feet (her ring size has increased twice in 3 years), a deepened voice, coarsened facial features, and new-onset hyperglycemia (fasting glucose 165 mg/dL). MRI reveals a 1.4 cm pituitary adenoma. Her IGF-1 is markedly elevated (380 ng/mL; normal range for her age roughly 100–200 ng/mL), and GH fails to suppress below 1 ng/mL during an oral glucose tolerance test (normal individuals suppress GH to <1 ng/mL because glucose loading should inhibit somatotroph secretion). Reasoning: her epiphyseal plates fused years ago at puberty, so the chronic GH/IGF-1 excess cannot lengthen her long bones — hence no increase in height. Instead, IGF-1 excess drives appositional (width-wise) bone growth and soft-tissue/cartilage proliferation, explaining the enlarged hands, feet, jaw, and facial features characteristic of acromegaly rather than gigantism. Simultaneously, GH's direct anti-insulin action — decreased peripheral glucose uptake and increased hepatic gluconeogenesis — explains her hyperglycemia; this is a case where the "diabetogenic" direct arm of GH action is clinically dominant even though the IGF-1 arm caused her presenting physical changes. Surgical removal of the adenoma (or medical suppression with a somatostatin analog, which directly mimics physiological somatostatin's inhibitory action on the tumor's GH secretion) is expected to normalize both IGF-1 and glucose tolerance.

Recombinant human GH (produced in E. coli using rDNA technology since 1985) is now the standard treatment for pediatric GH deficiency, Turner syndrome, chronic kidney disease-associated growth failure, and children born small for gestational age who fail to catch up. Its introduction ended the era of cadaveric pituitary-extracted GH, which had tragically transmitted Creutzfeldt-Jakob disease (a prion illness) to some recipients — a major driver of the switch to recombinant production. Recombinant IGF-1 (mecasermin) is used directly in patients with Laron syndrome and other forms of GH insensitivity, since giving them GH is futile. On the pathological end, somatostatin analogs (octreotide, lanreotide) and GH receptor antagonists (pegvisomant, which blocks GH receptor dimerization) are first-line or adjunct medical therapies for acromegaly when surgery cannot fully resect a GH-secreting adenoma. Measuring IGF-1 (rather than a single random GH level, given its pulsatility) is the standard biochemical screen for both GH excess and deficiency in clinical practice, precisely because IGF-1's longer half-life integrates GH secretion over time. In agriculture, recombinant bovine somatotropin (rBST) is used to increase milk yield in dairy cattle by amplifying the same GH-IGF-1 axis mechanisms described here, an application that remains a subject of ongoing public and regulatory debate in different countries. Athletic doping with recombinant GH exploits its anabolic, protein-sparing direct and IGF-1-mediated effects, and detecting exogenous GH abuse (which is chemically identical to endogenous GH) has driven the development of isoform-ratio and IGF-1/marker-based anti-doping assays.

Ask the tutor: How does the pulsatile pattern of GH secretion interact with sleep architecture and age to change growth velocity across childhood and puberty?